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a delayed rupture of the myocardium occurred sometime
after RFCA therapy and led to a slow accumulation of
hemopericardium.
Although we were not able to determine the exact site
of the chamber perforated, rupture of the right atrium
would have been unlikely. The immediate accumulation of
blood within the pericardium owing to the inability of
atrial tissue to locally contract and contain extravasation
would have acutely manifested itself as pericardial tam-
ponade.
The etiologic spectrum of constrictive pericarditis con-
sists of postradiotherapy, postoperative, and postinfec-
tious sequelae, as well as neoplasia, connective tissue
disorders, and autoimmune disease.3 A persistent intra-
pericardial hematoma induces pericardial inflamma-
tion, leading to granulation tissue, adhesions, and finally
constriction.4 Thus the possibility of an organized pericar-
dial hematoma should not be overlooked in the differen-
tial diagnosis of constrictive pericarditis after RFCA
therapy.
Definitive diagnosis and therapy of constricting pericar-
dial masses depends on operative removal as illustrated in
this report.
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MITRAL REGURGITATION LATE AFTER MANOUGUIAN’S ANULUS ENLARGEMENT AND AORTIC
VALVE REPLACEMENT
Kazuhito Imanaka, MD,a Shinichi Takamoto, MD,a and Akira Furuse, MD,b Tokyo, Japan
Anulus enlargement is necessary in some patients with
small aortic anuli. The Manouguian procedure1 usually
makes it possible to accommodate a prosthetic valve two
sizes larger than the original anulus and is applicable in
various situations.2-5 Although it is a well-established
method, its long-term results have not been well docu-
mented. Concern has been expressed about the long-term
effects of this procedure on mitral valve function, because
the structure of the anterior mitral leaflet and the mitral
anulus are inevitably altered. Herein we report that
significant mitral regurgitation (MR) often occurred late
after the Manouguian procedure performed with a pros-
thetic patch.
Clinical summary. Four patients (one man and three
women) underwent aortic valve replacement by means of the
Manouguian procedure with prosthetic patches because of
congenital aortic stenosis and a small anulus between 1981
and 1989. An expanded polytetrafluoroethylene (ePTFE)
patch was applied in three patients, and a woven Dacron
patch was used in one. Mean age at operation was 25 years.
The mean follow-up period was 134.5 months. The size of
the prosthetic valve was 21 mm in two patients, 19 mm in
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Fig. 2. Preoperative axial cine magnetic resonance image
at the ventricular level demonstrating a pericardial/epicar-
dial mass causing marked compromise of the right ven-
tricular chamber (arrowheads).
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one, and 17 mm in one. Mitral prolapse and MR developed
late after the operation in all four patients. In three of four
patients who had been followed up longer than 10 years,
mitral prolapse was marked and the grade of MR was
greater than moderate. One patient whose follow-up period
was 7 years had mild prolapse and mild MR. The anterior
leaflet prolapsed and regurgitant flow was oriented toward
the posterior wall of the left atrium. Mobility of the basal
portion of the anterior mitral leaflet was poor. This portion
was highly echogenic and thought to be prosthetic material.
On the other hand, the marginal portion of the anterior
leaflet was fully mobile but prolapsed. The echogenicity of
this portion was normal or only slightly enhanced. Inasmuch
as mobility differed markedly between the native mitral valve
and the prosthetic patch, the anterior leaflet appeared to
have a joint with a bend at the junction (Fig. 1). However,
the abnormal motion, prolapse, and MR were absent in the
early postoperative period. Serial echocardiographic studies
in two patients with an ePTFE patch revealed that the mitral
valve had initially appeared almost normal. Abnormal find-
ings in the mitral valve and MR became apparent about 5
years later and then deterioration increased (Fig. 2). Such an
abnormal motion or significant MR were not observed in
four patients in whom autologous pericardium had been
used as a patch, although mild mitral prolapse was com-
monly seen in these patients as well.
Comments. We found that significant MR resulting from
mitral prolapse was common in patients who had undergone
the Manouguian procedure with a prosthetic patch. It is clear
that poorly flexible, firm material is unsuitable for the patch,
because it forms a part of the mitral valve. However,
significant MR also occurred in patients in whom ePTFE, an
originally soft material, was used. The fact that the abnor-
malities in the mitral valve developed at a late postoperative
stage and were progressive strongly suggests that the cause of
MR in these patients was patch degeneration rather than an
Fig. 1. Typical motion of mitral valve late after the Manouguian procedure with a prosthetic patch. Left,
Systolic phase. Right, Diastolic phase. Because of the difference of mobility and stiffness between the
prosthetic patch (arrow) and the native valve, the anterior leaflet appears to be bent.
Fig. 2. Deterioration of abnormalities in the anterior mitral leaflet. Left, One year after the operation.
There was no MR. Middle, Six years later. Mild MR was observed. Right, Twelve years later. Moderate
degree of MR was present. Arrow, Prosthetic patch.
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inappropriate incision.2 We actually encountered strikingly
severe degeneration of ePTFE at a reoperation 7 years after
the Manouguian procedure. The patch was too stiff to
function as part of the heart valve, although prolapse and
MR were mild in this case. Therefore it appears better not to
use synthetic prosthetic patches that may degenerate later
on. In this regard, bioprosthetic material may also not be a
good choice for the patch. Even allografts are not free from
degeneration. In our experience, patients with an autologous
pericardial patch had better results. Abnormal motion of the
mitral valve or significant MR was not present in any of
them. However, shrinkage and sclerosing change of the
autologous pericardium are also well known. At present, the
ideal patch material for the Manouguian procedure does not
seem to exist. In addition, acceptable morphologic alteration
of the mitral anulus and the anterior leaflet in this procedure
is yet unclear, especially in pediatric patients. Therefore
every patient undergoing the Manouguian procedure needs
careful follow-up.
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APPLICATION OF A HEPARIN REMOVAL DEVICE IN PATIENTS WITH KNOWN PROTAMINE
HYPERSENSITIVITY
Joseph B. Zwischenberger, MD, Roger A. Vertrees, BA, CCP, Robert L. Brunston, Jr., MD, Weike Tao, MD,
Scott K. Alpard, MD, and Paul S. Brown, Jr., MD, Galveston, Tex.
Severe life-threatening reactions have been reported in
association with protamine use, including pulmonary hy-
pertension, systemic hypotension, and anaphylactic shock,
as well as thrombocytopenia, granulocytopenia, comple-
ment activation, and cytokine release.1 As an alternative
to protamine administration, a heparin removal device
(HRD, Research Medical Inc., Midvale, Utah) uses a
venovenous extracorporeal circuit with plasma separation
and poly-L-lysine affinity adsorption to remove heparin
from the blood.2 We3 previously reported the first com-
passionate clinical use of the HRD to decrease life-
threatening bleeding in a patient who could not tolerate
protamine. Through large animal studies, we4-6 have since
characterized the performance of the HRD and devel-
oped a heparin clearance mathematical model to deter-
mine the HRD run time needed for a targeted 90%
heparin removal based on first-order exponential deple-
tion. Variables affecting the HRD efficiency, such as
extracorporeal blood flow, sorbent amount, and cannula
placement, have likewise been improved. The HRD re-
turns activated clotting time (ACT) and other measured
coagulation variables to near baseline values in approxi-
mately 30 minutes in adult-sized subjects at the veno-
venous extracorporeal blood flow rate of 1400 ml/min
without any apparent adverse effects on hemodynamics.4-6
From May 6 to May 27, 1997, two patients scheduled for
elective coronary artery bypass grafting had documented
“hypersensitivity” to protamine, and the HRD was used as
an alternative to reverse systemic heparin anticoagulation.
Since the HRD has not been approved by the Food and
Drug Administration, approval for compassionate use was
obtained from the Institutional Review Board of the
University of Texas Medical Branch, Galveston, Texas,
and informed consent was obtained from each patient
before the operation.
Because of persistent angina after a recent myocardial
infarction, a 58-year-old woman underwent cardiac cath-
eterization demonstrating severe three-vessel disease. On
completion of her cardiac catheterization she was given
protamine (4 mg), resulting in dizziness, an urticarial
eruption, and hypotension (74/50 mm Hg). She was
treated with intravenous antihistamines (Benadryl 100
mg) and steroids (Solu-Medrol 125 mg) for a presumed
protamine reaction. She continued to be hypotensive,
despite treatment, and received 1.5 L of crystalloid solu-
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